Ironwood Pharmaceuticals Inc. (IRWD)

19.34
NASDAQ : Health Technology
Prev Close 18.61
Day Low/High 18.55 / 19.37
52 Wk Low/High 12.89 / 19.89
Avg Volume 1.41M
Exchange NASDAQ
Shares Outstanding 151.62M
Market Cap 3.08B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update

Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its first quarter 2016 results and recent business activities.

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 3:40 p.

Today's Dead Cat Bounce Stock: Ironwood Pharmaceuticals (IRWD)

Today's Dead Cat Bounce Stock: Ironwood Pharmaceuticals (IRWD)

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ironwood Pharmaceuticals Enters Into U.S. Licensing Agreement With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals Enters Into U.S. Licensing Agreement With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that it has entered into a licensing agreement with AstraZeneca plc for the exclusive U.

Ironwood Pharmaceuticals To Host First Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals To Host First Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2016 investor update conference call and webcast at 4:30 p.

Synergy Pharmaceuticals Soars After FDA Filing Accepted

Synergy Pharmaceuticals Soars After FDA Filing Accepted

Biotech company Synergy was rising by 9% on Tuesday. But is it a buy?

Ironwood Pharmaceuticals Appoints Andrew Dreyfus To Board Of Directors

Ironwood Pharmaceuticals Appoints Andrew Dreyfus To Board Of Directors

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Andrew Dreyfus, president and chief executive officer of Blue Cross Blue Shield of Massachusetts, to its board of directors.

Ironwood Pharmaceuticals Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis

Ironwood Pharmaceuticals Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that top-line data from an exploratory Phase IIa clinical study indicate IW-9179 did not meaningfully reduce the severity of symptoms in patients with...

Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Volume Stock

Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present Clinical And Preclinical Data On SGC Stimulators At Upcoming Scientific Conferences

Ironwood Pharmaceuticals To Present Clinical And Preclinical Data On SGC Stimulators At Upcoming Scientific Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the company and its academic collaborators will present clinical and preclinical data on several soluble guanylate cyclase (sGC) stimulators from...

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it initiated a Phase IIb clinical trial of IW-3718 in patients with refractory gastroesophageal reflux disease (GERD).

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 11:15 a.

Ironwood Pharmaceuticals To Present At Cowen And Company 36th Annual Health Care Conference

Ironwood Pharmaceuticals To Present At Cowen And Company 36th Annual Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Cowen and Company 36 th Annual Health Care Conference on Monday, March 7, 2016 at 1:20 p.

Updated 2016 Direct-to-Consumer Awareness Campaign For LINZESS® (linaclotide)

Updated 2016 Direct-to-Consumer Awareness Campaign For LINZESS® (linaclotide)

Ironwood Pharmaceuticals, Inc. announced today the launch of an updated 2016 direct-to-consumer (DTC) awareness campaign for LINZESS® (linaclotide).

Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that a new drug application (NDA) seeking approval of linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) in Japan...

Ironwood Pharmaceuticals (IRWD) Stock Gaining on Q4 Results

Ironwood Pharmaceuticals (IRWD) Stock Gaining on Q4 Results

Ironwood Pharmaceuticals (IRWD) stock is higher late Friday afternoon following the release of its 2015 fourth quarter results after yesterday’s closing bell.

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2015 Investor Update

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2015 results and recent business activities.

Ironwood Pharmaceuticals Progresses Vascular And Fibrotic Disease Platform With Positive Top-Line Phase Ia Data On Soluble Guanylate Cyclase Stimulator IW-1701

Ironwood Pharmaceuticals Progresses Vascular And Fibrotic Disease Platform With Positive Top-Line Phase Ia Data On Soluble Guanylate Cyclase Stimulator IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator from Ironwood's vascular and...

Ironwood Pharmaceuticals To Present At 2016 RBC Capital Markets Global Healthcare Conference

Ironwood Pharmaceuticals To Present At 2016 RBC Capital Markets Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 RBC Capital Markets Global Healthcare Conference on Wednesday, February 24, 2016 at 4:05 p.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2015 investor update conference call and webcast at 4:30 p.

(Graphic: Business Wire)

(Graphic: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed its strategy to build a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 34 th Annual J.

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Stocks with insider trader activity include ANCX, IRWD and MPLX

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc.

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase II clinical trial of linaclotide conducted in adults with opioid-induced constipation (OIC) met its primary endpoint.

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the January 2016 expiration.

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2015 and recent business activities.

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of a Phase Ib clinical study of IW-1973 and a Phase Ia clinical study of IW-1701, both of which are investigational soluble guanylate cyclase...

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release formulations of...

TheStreet Quant Rating: D (Sell)